These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

686 related articles for article (PubMed ID: 28477403)

  • 41. LncRNA TUG1 promoted viability and associated with gemcitabine resistant in pancreatic ductal adenocarcinoma.
    Yang F; Li X; Zhang L; Cheng L; Li X
    J Pharmacol Sci; 2018 Jun; 137(2):116-121. PubMed ID: 29960845
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Crosstalk Analysis between mPSCs and Panc1 Cells Identifies CCN1 as a Positive Regulator of Gemcitabine Sensitivity in Pancreatic Cancer Cells.
    Gündel B; Liu X; Pfützenreuter A; Engelsberger V; Weiskirchen R; Löhr JM; Heuchel R
    Int J Mol Sci; 2024 Aug; 25(17):. PubMed ID: 39273316
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combining gemcitabine and MSC delivering soluble TRAIL to target pancreatic adenocarcinoma and its stroma.
    Grisendi G; Dall'Ora M; Casari G; Spattini G; Farshchian M; Melandri A; Masicale V; Lepore F; Banchelli F; Costantini RC; D'Esposito A; Chiavelli C; Spano C; Spallanzani A; Petrachi T; Veronesi E; Ferracin M; Roncarati R; Vinet J; Magistri P; Catellani B; Candini O; Marra C; Eccher A; Bonetti LR; Horwtiz EM; Di Benedetto F; Dominici M
    Cell Rep Med; 2024 Aug; 5(8):101685. PubMed ID: 39168103
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MiR-125a regulates chemo-sensitivity to gemcitabine in human pancreatic cancer cells through targeting A20.
    Yao J; Li Z; Wang X; Xu P; Zhao L; Qian J
    Acta Biochim Biophys Sin (Shanghai); 2016 Feb; 48(2):202-8. PubMed ID: 26758190
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
    Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K
    Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prolactin receptor potentiates chemotherapy through miRNAs-induced G6PD/TKT inhibition in pancreatic cancer.
    Liao YN; Huang PQ; Pan H; Gai YZ; Zhan YF; Li SX; Nie HZ
    FASEB J; 2024 May; 38(10):e23705. PubMed ID: 38805171
    [TBL] [Abstract][Full Text] [Related]  

  • 47. YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic cancer.
    Li B; Xing F; Wang J; Wang X; Zhou C; Fan G; Zhuo Q; Ji S; Yu X; Xu X; Qin Y; Li Z
    Cancer Lett; 2024 Oct; 602():217197. PubMed ID: 39216548
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cytosolic 5'-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites.
    Patzak MS; Kari V; Patil S; Hamdan FH; Goetze RG; Brunner M; Gaedcke J; Kitz J; Jodrell DI; Richards FM; Pilarsky C; Gruetzmann R; Rümmele P; Knösel T; Hessmann E; Ellenrieder V; Johnsen SA; Neesse A
    EBioMedicine; 2019 Feb; 40():394-405. PubMed ID: 30709769
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in Mice.
    Peran I; Dakshanamurthy S; McCoy MD; Mavropoulos A; Allo B; Sebastian A; Hum NR; Sprague SC; Martin KA; Pishvaian MJ; Vietsch EE; Wellstein A; Atkins MB; Weiner LM; Quong AA; Loots GG; Yoo SS; Assefnia S; Byers SW
    Gastroenterology; 2021 Mar; 160(4):1359-1372.e13. PubMed ID: 33307028
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lysyl oxidase family activity promotes resistance of pancreatic ductal adenocarcinoma to chemotherapy by limiting the intratumoral anticancer drug distribution.
    Le Calvé B; Griveau A; Vindrieux D; Maréchal R; Wiel C; Svrcek M; Gout J; Azzi L; Payen L; Cros J; de la Fouchardière C; Dubus P; Guitton J; Bartholin L; Bachet JB; Bernard D
    Oncotarget; 2016 May; 7(22):32100-12. PubMed ID: 27050073
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
    Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
    Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer.
    Qian W; Li J; Chen K; Jiang Z; Cheng L; Zhou C; Yan B; Cao J; Ma Q; Duan W
    Life Sci; 2018 Sep; 208():253-261. PubMed ID: 30053447
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
    Wang X; Xie J; Lu X; Li H; Wen C; Huo Z; Xie J; Shi M; Tang X; Chen H; Peng C; Fang Y; Deng X; Shen B
    Cancer Lett; 2017 Jul; 399():1-9. PubMed ID: 28428074
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
    Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
    Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cancer-associated fibroblast-derived exosomal microRNA-24-3p enhances colon cancer cell resistance to MTX by down-regulating CDX2/HEPH axis.
    Zhang HW; Shi Y; Liu JB; Wang HM; Wang PY; Wu ZJ; Li L; Gu LP; Cao PS; Wang GR; Ma YS; Fu D
    J Cell Mol Med; 2021 Apr; 25(8):3699-3713. PubMed ID: 33621425
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Contrasting roles of H3K4me3 and H3K9me3 in regulation of apoptosis and gemcitabine resistance in human pancreatic cancer cells.
    Lu C; Yang D; Sabbatini ME; Colby AH; Grinstaff MW; Oberlies NH; Pearce C; Liu K
    BMC Cancer; 2018 Feb; 18(1):149. PubMed ID: 29409480
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vimentin Expression in Tumor Microenvironment Predicts Survival in Pancreatic Ductal Adenocarcinoma: Heterogeneity in Fibroblast Population.
    Maehira H; Miyake T; Iida H; Tokuda A; Mori H; Yasukawa D; Mukaisho KI; Shimizu T; Tani M
    Ann Surg Oncol; 2019 Dec; 26(13):4791-4804. PubMed ID: 31583548
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Skeletal Muscle-Derived Irisin Enhances Gemcitabine Sensitivity and Suppresses Migration Ability in Pancreatic Ductal Adenocarcinoma.
    Sugimoto T; Iwagami Y; Kobayashi S; Yamanaka C; Sasaki K; Yamada D; Tomimaru Y; Asaoka T; Noda T; Takahashi H; Shimizu J; Doki Y; Eguchi H
    Ann Surg Oncol; 2024 Jun; 31(6):3718-3736. PubMed ID: 38502294
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Novel crosstalk between KLF4 and ZEB1 regulates gemcitabine resistance in pancreatic ductal adenocarcinoma.
    Wang Z; Chen Y; Lin Y; Wang X; Cui X; Zhang Z; Xian G; Qin C
    Int J Oncol; 2017 Oct; 51(4):1239-1248. PubMed ID: 28849150
    [TBL] [Abstract][Full Text] [Related]  

  • 60. LncRNA LUCAT1 contributes to cell proliferation and migration in human pancreatic ductal adenocarcinoma via sponging miR-539.
    Nai Y; Pan C; Hu X; Ma Y
    Cancer Med; 2020 Jan; 9(2):757-767. PubMed ID: 31789465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.